Share on LinkedInShare on LinkedIn

ARTICLE · 08 JULY 2024

PTAB Invalidates Regeneron Claims On Method Of Treatment

The Patent Trial and Appeal Board (PTAB) issued a final written decision on IPR2023-00442 determining that claims 1, 3-11, 13, 14, 16-24, and 26 of U.S.

United StatesIntellectual Property

The Patent Trial and Appeal Board (PTAB) issued a final written decision on IPR2023-00442 determining that claims 1, 3-11, 13, 14, 16-24, and 26 of U.S. Patent No. 10,130,681 ("the '681 patent") were unpatentable. The '681 patent is owned by Regeneron Pharmaceuticals, Inc., and was challenged in an IPR by Samsung Bioepis Co., Ltd. The '681 patent claims priority to a number of patents that were invalidated in previous IPR proceedings.

The claims of the '681 patent are directed to a method of treating an angiogenic eye disorder by administering a vascular endothelial growth factor (VEGF) antagonist according to the following dosage pattern: an initial dose, a secondary dose 2-4 weeks after the initial dose, and a tertiary dose at least 8 weeks after the secondary dose. The claims also include exclusion criteria for patients who have active or recent ocular infections or inflammation.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from